Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Market Cap	106.71B +86.6%
Revenue (ttm)	2.29B +6.5%
Net Income	-425.06M
EPS	-1.84
Shares Out	233.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	675,495
Average Volume	581,563
Open	424.40
Previous Close	427.40
Day's Range	416.80 - 462.00
52-Week Range	228.20 - 581.00
Beta	0.45
RSI	63.20
Earnings Date	Mar 23, 2026

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally. Its product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,870
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2025, HKG:6990's revenue was 2.06 billion, an increase of 6.46% compared to the previous year's 1.93 billion. Losses were -381.97 million, 43.2% more than in 2024.

Financial numbers in CNY